Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Collegium Pharmaceutical Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Collegium Pharmaceutical Inc. May 14, 202699.1%
-
Karyopharm Therapeutics Inc. May 28, 202575.6%
-
Collegium Pharmaceutical Inc. May 15, 202599.5%
-
Collegium Pharmaceutical Inc. May 16, 202499.1%
-
Collegium Pharmaceutical Inc. May 18, 202399.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 21, 2026 | Karyopharm Therapeutics Inc. | Grant or award | +15,508 | — | — |
| May 14, 2026 | Collegium Pharmaceutical Inc. | Grant or award | +8,741 | — | — |
| May 11, 2026 | Collegium Pharmaceutical Inc. | Option exercise | +8,700 | $16.49 | $143,463 |
| May 11, 2026 | Collegium Pharmaceutical Inc. | Open-market sale | −8,700 | $37.18 | $323,466 |
| May 15, 2025 | Collegium Pharmaceutical Inc. | Grant or award | +9,791 | — | — |
| May 16, 2024 | Collegium Pharmaceutical Inc. | Grant or award | +7,693 | — | — |
| May 14, 2024 | Collegium Pharmaceutical Inc. | Option exercise | +28,985 | $5.73 | $166,084 |
| May 14, 2024 | Collegium Pharmaceutical Inc. | Open-market sale | −28,985 | $32.30 | $936,216 |
| Sep 12, 2023 | Karyopharm Therapeutics Inc. | Open-market purchase | +41,140 | $1.22 | $50,191 |
| May 18, 2023 | Collegium Pharmaceutical Inc. | Grant or award | +9,792 | — | — |
Questions about Garen G. Bohlin
What boards is Garen G. Bohlin on?
Garen G. Bohlin sits on the boards of Collegium Pharmaceutical Inc. and Karyopharm Therapeutics Inc.
How long has Garen G. Bohlin served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.